Innoviva, Inc. (INVA)
NASDAQ·Healthcare·Biotechnology
$23.66
+1.28%
Mkt Cap $1.51B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 25, 2026 | $102.62M | $114.61M | +11.68% | $0.34 | $1.94 | +470.59% | — | — |
| Q4 2025 Nov 5, 2025 | $101.53M | $107.80M | +6.18% | $0.46 | $1.08 | +134.78% | — | — |
| Q3 2025 Aug 6, 2025 | $90.88M | $100.28M | +10.34% | $0.57 | $0.77 | +35.09% | — | — |
| Q2 2025 May 7, 2025 | $82.67M | $88.63M | +7.21% | $0.29 | $0.25 | -13.79% | — | — |
| Q1 2025 Feb 26, 2025 | $92.59M | $91.81M | -0.85% | $0.34 | $0.57 | +67.65% | — | — |
| Q4 2024 Nov 6, 2024 | $88.15M | $89.51M | +1.54% | $0.27 | $0.02 | -92.59% | — | — |
| Q3 2024 Jul 31, 2024 | $74.69M | $103.35M | +38.38% | $0.24 | $0.68 | +183.33% | — | — |
| Q2 2024 May 8, 2024 | $68.00M | $80.95M | +19.05% | $0.17 | $0.46 | +170.59% | — | — |
| Q1 2024 Feb 29, 2024 | $75.51M | $89.27M | +18.23% | $0.23 | $0.76 | +230.43% | — | — |
| Q4 2023 Nov 1, 2023 | $75.51M | $67.26M | -10.93% | $0.27 | $0.98 | +262.96% | — | — |
| Q3 2023 Aug 2, 2023 | $68.92M | $80.99M | +17.52% | $0.26 | $0.08 | -69.23% | — | — |
| Q2 2023 May 9, 2023 | $62.01M | $76.37M | +23.16% | $0.23 | $0.42 | +82.61% | — | — |
| Q1 2023 Feb 28, 2023 | $58.85M | $65.80M | +11.81% | $0.41 | $0.25 | -39.02% | — | — |
| Q4 2022 Nov 9, 2022 | $62.60M | $67.26M | +7.44% | $2.75 | $0.60 | -78.18% | — | — |
| Q3 2022 Jul 27, 2022 | $214.78M | $108.22M | -49.61% | $0.55 | $0.05 | -90.91% | — | — |
| Q2 2022 Apr 27, 2022 | $86.40M | $90.06M | +4.23% | $0.40 | $0.42 | +5.00% | — | — |
| Q1 2022 Feb 9, 2022 | $106.37M | $107.68M | +1.23% | $0.41 | $0.55 | +34.15% | — | — |
| Q4 2021 Oct 27, 2021 | $76.04M | $97.86M | +28.69% | $0.43 | $0.90 | +109.30% | — | — |
| Q3 2021 Jul 28, 2021 | $111.23M | $100.81M | -9.37% | $0.29 | $0.90 | +210.34% | — | — |
| Q2 2021 Apr 28, 2021 | — | $85.52M | — | -$0.01 | $0.84 | +8500.00% | — | — |